|1.||Overgaard, Jens: 10 articles (10/2015 - 09/2003)|
|2.||Eriksen, Jesper Grau: 4 articles (07/2015 - 10/2005)|
|3.||Alsner, Jan: 4 articles (09/2013 - 10/2005)|
|4.||Horsman, Michael R: 3 articles (10/2015 - 10/2005)|
|5.||Grau, Cai: 3 articles (10/2015 - 09/2003)|
|6.||Shouman, Tarek: 2 articles (10/2015 - 07/2015)|
|7.||Strojan, Primoz: 2 articles (10/2015 - 07/2015)|
|8.||Hassan Metwally, Mohamed A: 2 articles (10/2015 - 07/2015)|
|9.||Ali, Rubina: 2 articles (10/2015 - 07/2015)|
|10.||Kuddu, Maire: 2 articles (10/2015 - 07/2015)|
01/01/2010 - "Tumour hypoxia induces radioresistance and the randomised DAHANCA 5 trial found that the hypoxic cell radiosensitiser nimorazole significantly improved the outcome in HNSCC. "
09/01/2013 - "The aim of the present study was to determine radiosensitivity, the impact of hypoxia and the effect of Nimorazole in HPV positive and HPV negative cell lines. "
02/01/2015 - "(18)F-FAZA PET may be useful to guide hypoxia-directed RT using nimorazole as radiosensitizer. "
09/01/2013 - "The clinical observation that HPV positive patients do not seem to benefit from Nimorazole treatment is not due to inherent differences in hypoxia sensitivity or response to Nimorazole, but can be accounted for by the overall higher radiosensitivity of HPV positive cells."
09/01/2013 - "Although HPV positive cells had a markedly higher radiosensitivity compared to HPV negative cells, they displayed the same relative radioresistance under hypoxia and the same relative sensitizer effect of Nimorazole. "
|2.||Head and Neck Neoplasms (Head and Neck Cancer)
03/01/2015 - "Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial."
01/01/2003 - "Treatment of head and neck cancer with CHART and nimorazole: phase II study."
05/01/2014 - "To evaluate the compliance and toxicity of the hypoxic radiosensitizer nimorazole in head and neck cancer patients. "
01/01/2003 - "Nimorazole is the only such agent to have shown a significant effect in a randomized controlled trial in head and neck cancer. "
11/01/1998 - "Accordingly, we have combined nimorazole, the only hypoxic radiosensitizer shown to significantly improve local control in head and neck cancer, with continuous hyperfractionated accelerated radiation therapy (CHART). "
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
03/01/2015 - "To study the pharmacokinetic characteristics of the hypoxic radiosensitiser nimorazole in patients with head and neck squamous cell carcinoma. "
05/01/2014 - "Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC)."
07/01/2015 - "To test the hypothesis that radiotherapy (RT) of head and neck squamous cell carcinoma (HNSCC) can be improved by hypoxic modification using nimorazole (NIM) in association with accelerated fractionation. "
10/01/2015 - "Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole."
07/01/2015 - "A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma."
12/01/1973 - "[Study of Nimorazole in Trichomonas genital infections]."
01/01/1973 - "Letter: Effectiveness of nitrimidazine in treatment of Balantidium coli infections."
02/01/1979 - "Both forms of infection with IR-78 could always be cured with therapeutically acceptable doses of tinidazole and nimorazole; subcutaneous infections could not be cured with tolerated doses of metronidazole."
06/01/1983 - "CG 10213-Go, a 5-nitroimidazole derivative synthesized at the CIBA-Geigy Research Centre, Bombay, proved superior to such currently used 5-nitroimidazole derivatives as metronidazole, ornidazole, secnidazole, tinidazole and nimorazole, against experimental amoebic infections of the liver and caecum in a golden hamster model. "
|5.||DNA (Deoxyribonucleic Acid)
|8.||tirapazamine (SR 4233)
|2.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
|3.||Photochemotherapy (Photodynamic Therapy)